WESPAC Advisors SoCal LLC Increases Stock Holdings in BeOne Medicines Ltd. – Sponsored ADR $ONC

WESPAC Advisors SoCal LLC increased its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 66.6% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 4,925 shares of the company’s stock after acquiring an additional 1,968 shares during the period. WESPAC Advisors SoCal LLC’s holdings in BeOne Medicines were worth $1,463,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Cetera Investment Advisers acquired a new stake in BeOne Medicines in the second quarter valued at approximately $455,000. Rhumbline Advisers acquired a new position in shares of BeOne Medicines during the second quarter worth $275,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of BeOne Medicines in the second quarter valued at $505,000. Invesco Ltd. purchased a new position in shares of BeOne Medicines in the second quarter valued at $422,000. Finally, EverSource Wealth Advisors LLC acquired a new stake in BeOne Medicines during the 2nd quarter valued at $68,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Insider Buying and Selling at BeOne Medicines

In related news, CFO Aaron Rosenberg sold 631 shares of BeOne Medicines stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $257.74, for a total value of $162,633.94. Following the completion of the transaction, the chief financial officer directly owned 397,891 shares in the company, valued at approximately $102,552,426.34. This trade represents a 0.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Xiaobin Wu sold 1,484 shares of BeOne Medicines stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $269.37, for a total value of $399,745.08. Following the completion of the transaction, the chief operating officer owned 40 shares of the company’s stock, valued at approximately $10,774.80. The trade was a 97.38% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 21,466 shares of company stock valued at $5,768,875. Corporate insiders own 6.19% of the company’s stock.

BeOne Medicines Price Performance

ONC stock opened at $270.15 on Friday. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The firm has a 50 day simple moving average of $295.32 and a 200-day simple moving average of $312.15. The company has a market capitalization of $29.64 billion, a P/E ratio of 60.44 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $239.25 and a twelve month high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The firm had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. On average, equities research analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ONC has been the topic of several analyst reports. Wells Fargo & Company assumed coverage on shares of BeOne Medicines in a research note on Monday, May 4th. They set an “overweight” rating and a $400.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Morgan Stanley restated an “overweight” rating and set a $395.00 target price on shares of BeOne Medicines in a research note on Thursday, May 7th. Leerink Partners raised their target price on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research note on Friday, May 15th. Finally, Wall Street Zen lowered BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, BeOne Medicines has a consensus rating of “Moderate Buy” and a consensus target price of $390.00.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.